Published in Gut on February 04, 2009
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One (2011) 0.98
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95
Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol (2011) 0.94
Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One (2010) 0.94
CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology (2013) 0.93
Innate immune function in placenta and cord blood of hepatitis C--seropositive mother-infant dyads. PLoS One (2010) 0.88
Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol (2014) 0.86
Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. Hum Vaccin Immunother (2013) 0.84
Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology (2012) 0.83
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol (2013) 0.77
Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. J Clin Cell Immunol (2014) 0.77
Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. Indian J Med Res (2013) 0.77
Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: an Egyptian study. World J Gastroenterol (2013) 0.76
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. J Gastroenterol (2011) 0.76
Coxiella burnetii Induces Inflammatory Interferon-Like Signature in Plasmacytoid Dendritic Cells: A New Feature of Immune Response in Q Fever. Front Cell Infect Microbiol (2016) 0.75
HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. Sci Rep (2016) 0.75
Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol (2016) 0.75
Human Plasmacytoid Dendritic Cells Elicited Different Responses after Infection with Pathogenic and Nonpathogenic Junin Virus Strains. J Virol (2015) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Taking dendritic cells into medicine. Nature (2007) 11.82
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol (2000) 6.04
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 5.33
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Characterization of human blood dendritic cell subsets. Blood (2002) 3.97
BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med (2001) 3.40
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol (1999) 2.44
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis (2002) 2.08
Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology (2000) 2.02
Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84
Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol (2006) 1.82
Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol (2004) 1.75
Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol (2001) 1.74
Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis (2004) 1.70
Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr Opin Immunol (2007) 1.70
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology (2008) 1.57
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 1.36
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology (2005) 1.33
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 1.31
Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol (2003) 1.26
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology (2005) 1.20
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med (2007) 1.20
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine (2007) 1.14
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology (2006) 1.13
TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol (2007) 1.08
Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 0.99
Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatol (2007) 0.98
Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J Med Virol (2008) 0.94
Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transpl (2006) 0.92
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology (2007) 0.90
Human peripheral blood dendritic cells and monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses. Scand J Immunol (2007) 0.85
Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection? Hepatology (2007) 0.78
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Sacral nerve stimulation in patients with severe constipation. Dis Colon Rectum (2008) 2.25
To C or not to C: these are the questions in renal transplantation. Transplantation (2000) 2.24
EUS in cirrhotic patients with and without prior variceal hemorrhage in comparison with noncirrhotic control subjects. Gastrointest Endosc (2000) 1.94
Human triploidy: relationship between parental origin of the additional haploid complement and development of partial hydatidiform mole. Ann Hum Genet (1982) 1.86
Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol (1999) 1.77
Electroanatomic left ventricular mapping in the porcine model of healed anterior myocardial infarction. Correlation with intracardiac echocardiography and pathological analysis. Circulation (1999) 1.72
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol (1999) 1.62
Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0. Am J Gastroenterol (2000) 1.53
Efficacy and tolerance of a new gentamicin collagen fleece (Septocoll) after surgical treatment of a pilonidal sinus. Colorectal Dis (2003) 1.51
Overdrive stimulation of functional reentrant circuits causing ventricular tachycardia in the infarcted canine heart. Resetting and entrainment. Circulation (1993) 1.47
Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med (2001) 1.47
Effects of linear, irrigated-tip radiofrequency ablation in porcine healed anterior infarction. J Cardiovasc Electrophysiol (2001) 1.44
Hemispheric dominance for emotions, empathy and social behaviour: evidence from right and left handers with frontotemporal dementia. Neurocase (2001) 1.44
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Conduction block in the inferior vena caval-tricuspid valve isthmus: association with outcome of radiofrequency ablation of type I atrial flutter. J Am Coll Cardiol (1996) 1.21
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol (2008) 1.17
Holarctic phylogeography of Arctic charr (Salvelinus alpinus L.) inferred from mitochondrial DNA sequences. Evolution (2001) 1.16
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol (1999) 1.16
Safety and efficacy of dynamic muscle plasty for anal incontinence: lessons from a prospective, multicenter trial. Gastroenterology (1999) 1.14
Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology (2011) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Late mortality after orthotopic liver transplantation. Am J Surg (2001) 1.12
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol (2008) 1.11
Standards for anal sphincter replacement. Dis Colon Rectum (2000) 1.10
Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet (1992) 1.08
Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterization. J Immunol Methods (2000) 1.07
A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J (2005) 1.06
Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation (1995) 1.06
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One (2008) 1.02
Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg (1999) 1.01
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Improving the safety of laparoscopic cholecystectomy: the routine use of preoperative magnetic resonance cholangiography. Surg Endosc (2005) 0.99
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology (2006) 0.99
Sacral nerve stimulation for neurogenic faecal incontinence. Br J Surg (2007) 0.99
Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg (1999) 0.98
Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer (1989) 0.97
Improvement of perineal wound healing by local administration of gentamicin-impregnated collagen fleeces after abdominoperineal excision of rectal cancer. Am J Surg (2001) 0.95
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One (2010) 0.95
Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology (2007) 0.95
Quality of life after surgery for rectal cancer: do we still need a permanent colostomy? Dis Colon Rectum (1999) 0.93
Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol (1992) 0.93
Crystal engineering in the gem-alkynol family: the key role of water in the structure of 2,3,5,6-tetrabromo-trans-1,4-diethynyl-cyclohexa-2,5-diene-1,4-diol dihydrate determined by X-ray and neutron diffraction at 150 K. Acta Crystallogr B (2001) 0.93
5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res (1997) 0.92
Cells with haematopoietic stem cell phenotype in adult human endometrium: relevance to infertility? Hum Reprod (2007) 0.92
Biliary tract complications of side-to-side without T tube versus end-to-end with or without T tube choledochocholedochostomy in liver transplant recipients. Transplantation (1998) 0.92
Aetiology and surgical management of toxic megacolon. Colorectal Dis (2006) 0.92
Shock-induced depolarization of refractory myocardium prevents wave-front propagation in defibrillation. Circ Res (1996) 0.92
Genetic architecture of survival and fitness-related traits in two populations of Atlantic salmon. Heredity (Edinb) (2013) 0.91
Anisotropic reentry in the epicardial border zone of myocardial infarcts. Ann N Y Acad Sci (1990) 0.90
Effects of neonatal serotonin depletion on the development of rat dentate granule cells. Brain Res Dev Brain Res (1997) 0.90
Lower frequency (5 MHZ) intracardiac echocardiography in a large swine model: imaging views and research applications. Ultrasound Med Biol (1997) 0.90
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology (2009) 0.89
Low-energy impedance-compensating biphasic waveforms terminate ventricular fibrillation at high rates in victims of out-of-hospital cardiac arrest. LIFE Investigators. J Cardiovasc Electrophysiol (1997) 0.89
Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg (2000) 0.88
Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic hepatitis C virus infection. J Hepatol (2000) 0.87
Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun (2008) 0.87
Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord (2003) 0.86
MR imaging for the preoperative planning of sphincter-saving surgery for tumors of the lower third of the rectum: use of intravenous and endorectal contrast materials. Radiology (2000) 0.86
A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer. Br J Cancer (1994) 0.86
Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med (2000) 0.86
Liver transplantation for disulfiram-induced hepatic failure. Am J Gastroenterol (1998) 0.85
Patients' expectations of colorectal surgery for cancer. Colorectal Dis (2006) 0.84
Hepatic regeneration: current concepts and clinical implications. Semin Liver Dis (1994) 0.84
Complete and partial hydatidiform mole in Hawaii: cytogenetics, morphology and epidemiology. Br J Obstet Gynaecol (1982) 0.84
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res (1982) 0.84
Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. Transplant Proc (2002) 0.82
Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res Hum Retroviruses (1999) 0.82
Diagnosis and tactical approach to surgery for early gastric carcinoma: a retrospective analysis of the past 16 years in an Austrian general hospital. Gastroenterol Jpn (1989) 0.82
Synchrony of malignant lymphoma and breast cancer. JAMA (1990) 0.82
[Collateral circulation of the left colon: historic considerations and actual clinical significance]. Chirurg (2003) 0.82
Preservation and restoration of sphincter function in patients with rectal cancer. Can J Gastroenterol (2000) 0.82
Mitochondrial DNA identification of game and harvested freshwater fish species. Forensic Sci Int (2006) 0.81
Intracardiac echocardiographic evaluation of ventricular mural swelling from radiofrequency ablation in chronic myocardial infarction: irrigated-tip versus standard catheter. J Interv Card Electrophysiol (2001) 0.81
[Breast cancer in the male--a retrospective analysis of 15 cases]. Onkologie (1990) 0.81
Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. J Viral Hepat (2013) 0.81
CD44 expression in benign and malignant colorectal polyps. Dis Colon Rectum (1999) 0.80
Hyperactive and aggressive behaviors in childhood: intertwined dimensions. J Abnorm Child Psychol (1981) 0.80
Accommodation and relocation decision making in continuing care retirement communities. Health Soc Work (1991) 0.79
Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl (2001) 0.79
Lessons from the implementation of CCRC regulation. Gerontologist (1990) 0.79
Psychogenic amnesia. Am Fam Physician (1990) 0.79
Spatial factors and the behavior of nonhuman primates. Folia Primatol (Basel) (1972) 0.79
The use of naturopathic remedies for chronic liver disease. Am J Gastroenterol (1996) 0.79
[ Topography of carpal bone - An experimental model for carpal tunnel syndrome ]. Acta Anat (Basel) (1990) 0.79
Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant (2014) 0.78
Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D. Neoplasma (1993) 0.78
Current legislation concerning life care and continuing care contracts. Gerontologist (1987) 0.78
Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study. Breast Cancer Res Treat (1991) 0.77